Skip to main content
SNY
NASDAQ Life Sciences

赛诺菲的文格鲁司他获得FDA突破性疗法认定，用于治疗3型戈谢病

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$44.07
Mkt Cap
$106.81B
52W Low
$43.34
52W High
$59.165
Market data snapshot near publication time

summarizeSummary

赛诺菲的研究药物文格鲁司他获得了美国FDA的突破性疗法认定，用于治疗3型戈谢病（GD3）的神经系统症状。这个重要的监管里程碑是基于阳性第三阶段LEAP2MONO研究数据，数据表明神经系统症状有统计学意义上的显著改善。这个认定凸显了GD3患者的巨大未满足的医疗需求，因为目前没有批准的治疗方法来治疗这种罕见的溶酶体存储疾病的神经系统症状。突破性疗法认定将加速开发和审查过程，可能加快文格鲁司他进入市场的步伐，并加强赛诺菲的罕见疾病管道。投资者应该关注即将到来的全球监管申报和进一步的研究结果展示。

在该公告发布时，SNY的交易价格为$44.07，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1068.1亿。 52周交易区间为$43.34至$59.17。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed SNY - Latest Insights

SNY
Apr 29, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
7
Sanofi Prices €2.3 Billion Multi-Tranche Bond Issue for General Corporate Purposes
Sentiment: Neutral
View Wiseek Article
SNY
Apr 27, 2026, 12:58 PM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Secures Key FDA Approvals for Dupixent and Tzield, Despite Sarclisa Delay
Sentiment: Positive
View Wiseek Article
SNY
Apr 24, 2026, 6:09 AM EDT
Source: GlobeNewswire
Importance Score:
8
EU Regulators Recommend Sanofi's Cenrifki for Secondary Progressive MS Approval
Sentiment: Positive
View Wiseek Article
SNY
Apr 23, 2026, 7:20 AM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Reports Strong Q1 Double-Digit Sales & EPS Growth, Multiple Regulatory Approvals, and Pipeline Advancements
Sentiment: Positive
View Wiseek Article
SNY
Apr 18, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Sanofi's Nuvaxovid COVID-19 Vaccine Shows Superior Tolerability in Head-to-Head Study
Sentiment: Positive
View Wiseek Article
SNY
Apr 15, 2026, 6:57 AM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Reports Positive Phase 2 Lunsekimig Data and EU Approval for Dupixent in Young Children with CSU
Sentiment: Positive
View Wiseek Article
SNY
Apr 07, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Sanofi's Lunsekimig Meets Phase 2 Endpoints in Asthma and CRSwNP, Bolstering Respiratory Pipeline
Sentiment: Positive
View Wiseek Article
SNY
Mar 31, 2026, 12:19 PM EDT
Filing Type: 6-K
Importance Score:
7
Sanofi Reports Positive Phase 3 Amlitelimab Data for Atopic Dermatitis, Advances Pipeline
Sentiment: Positive
View Wiseek Article
SNY
Mar 31, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Sanofi's Rezurock Secures EU Conditional Approval for Chronic Graft-vs-Host Disease
Sentiment: Positive
View Wiseek Article
SNY
Mar 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
CHMP Recommends EU Approval for Sanofi's Innovative Sarclisa On-Body Injector for Multiple Myeloma
Sentiment: Positive
View Wiseek Article